Pharmaceutical formulations of potassium ATP channel openers and uses thereof
Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K ATP channel openers with other drugs to treat diseases of humans and animals.
1. A method of treating hyperphagia associated with Prader Willi Syndrome, said method comprising administering a pharmaceutical formulation of diazoxide to a subject in need thereof.
2. The method of claim 1 , wherein the pharmaceutical formulation is orally administered.
3. The method of claim 2 , wherein the pharmaceutical formulation includes at least one excipient which affects the rate of release of diazoxide.
4. The method of claim 2 , wherein the pharmaceutical formulation includes at least one excipient that delays release of diazoxide.
5. The method of claim 1 , wherein the pharmaceutical formulation includes at least one other active ingredient.
6. The method of claim 2 , wherein the pharmaceutical formulation includes at least one other active ingredient.
7. The method of claim 3 , wherein the pharmaceutical formulation includes at least one other active ingredient.
8. The method of claim 4 , wherein the pharmaceutical formulation includes at least one other active ingredient.
9. The method of claim 2 , wherein the pharmaceutical formulation is administered twice per day.
10. The method of claim 2 , wherein the pharmaceutical formulation is administered once per day.